natgillin/translations-raw huggingface dataset:
No dose adjustment is necessary in patients with hepatic impairment.
Pri bolnikih z jetrno okvaro ni potrebno prilagajanje odmerka.
No dose adjustment is necessary in patients with impaired renal function (creatinine clearance >4 ml/min) (see section 5.2).
Pri bolnikih z okvarjenim delovanjem ledvic (očistek kreatinina > 4 ml/min) odmerka ni treba prilagajati (glejte poglavje 5.2).
No dose adjustment is necessary in patients with impaired renal function.
Bolnikom z ledvično okvaro odmerka ni treba prilagajati.
No dose adjustment is necessary in patients with mild hepatic impairment.
Pri bolnikih z blago okvaro jeter prilagajanje odmerkov ni potrebno.
No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh Classes A and B) (see sections 4.4 and 5.2).
Pri bolnikih z blago ali zmerno jetrno okvaro, prilagoditev odmerka ni potrebna (Child-Pugh razred A in B) (glejte poglavji 4.4 in 5.2).
No dose adjustment is necessary in patients with mild or moderate renal impairment (see section 5.2).
Pri bolnikih z blago ali zmerno okvaro ledvic odmerka ni treba prilagajati (glejte poglavje 5.2).
No dose adjustment is necessary in patients with mild renal impairment (CrCL 50- ≤ 80 mL/min).
Bolnikom z blago ledvično okvaro (CrCl 50 do ≤ 80 ml/min) odmerka ni treba prilagoditi.
No dose adjustment is necessary in patients with mild renal impairment (CrCL 50- ≤ 80 mL/min).
Pri bolnikih z blago ledvično okvaro (CrCl 50 - ≤ 80 ml/min) prilagajanje odmerka ni potrebno.
No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance 50 - 80 ml/min) (see section 5.2).
Bolnikom z blago (očistek kreatinina 50 - 80 ml/min) okvaro ledvic odmerka ni treba prilagajati (glejte poglavje 5.2).
No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance 50 - 80 ml/min) or moderate renal impairment (creatinine clearance 30 - 49 ml/min) (see section 5.2).
Bolnikom z blago (očistek kreatinina 50 - 80 ml/min) ali zmerno (očistek kreatinina 30 - 49 ml/min) okvaro ledvic odmerka ni treba prilagajati (glejte poglavje 5.2).
No dose adjustment is necessary in patients with mild to moderate hepatic impairment (see section 5.2).
Pri bolnikih z blagimi do zmernimi okvarami jeter ni potrebno prilagajanje odmerka (glejte poglavje 5.2).
No dose adjustment is necessary in patients with mild to moderate hepatic impairment (see sections 4.4 and 5.2).
Bolnikom z blago do zmerno jetrno okvaro odmerka ni treba prilagajati (glejte poglavji 4.4 in 5.2).
No dose adjustment is necessary in patients with mild to moderate hepatic impairment.
Bolnikom z blago do srednje hudo jetrno okvaro odmerka ni treba prilagajati.
No dose adjustment is necessary in patients with renal impairment (see section 5.2).
Pri bolnikih z motnjami v delovanju ledvic prilagoditev odmerka ni potrebna (glejte poglavje 5.2).
No dose adjustment is necessary in patients with renal impairment.
Pri bolnikih z ledvično okvaro prilagajanje odmerkov ni potrebno.
No dose adjustment is necessary in patients with renal impairment.
Pri bolnikih z okvaro ledvic prilagajanje odmerjanja ni potrebno.
No dose adjustment is necessary in patients with renal insufficiency.
Pri bolnikih z ledvično insuficienco ni potrebno prilagajati odmerka.
No dose adjustment is necessary in the elderly (see sections 4.4 and 5.2).
Pri starejših odmerka ni treba prilagajati (glejte poglavji 4.4 in 5.2).
No dose adjustment is necessary in this population.
Prilagoditev odmerka v tej populaciji ni potrebna.
No dose adjustment is necessary in TIH patients with serum creatinine < 400 μmol/l or < 4.5 mg/dl (see section 4.4).
Pri bolnikih s tumorsko povzročeno hiperkalciemijo (TIH), s serumskim kreatininom < 400 µmol/l ali < 4,5 mg/dl, ni potrebno prilagajanje odmerjanja (glejte poglavje 4.4).
No dose adjustment is necessary in TIH patients with serum creatinine < 400 μmol/l or < 4.5 mg/dl (see section 4.4).
Pri bolnikih s tumorsko povzročeno hiperkalciemijo (TIH), s serumskim kreatininom < 400 μmol/l ali < 4,5 mg/dl, ni potrebno prilagajanje odmerjanja (glejte poglavje 4.4).
No dose adjustment is necessary when CYP3A inhibitors are initiated in patients currently taking Orkambi.
Kadar uvajamo zaviralce CYP3A pri bolnikih, ki trenutno jemljejo zdravilo Orkambi, ni potrebno prilagajanje odmerka.
No dose adjustment is necessary when Triumeq is combined with nucleoside reverse transcript inhibitors.
Kadar se zdravilo Triumeq uporablja v kombinaciji z nukleozidnimi zaviralci reverzne transkriptaze prilagajanje
No dose adjustment is necessary when Xtandi is co-administered with inducers of CYP2C8 or CYP3A4.
V primeru sočasne uporabe zdravila Xtandi z induktorji CYP2C8 ali CYP3A4 prilagoditev odmerka ni potrebna
No dose adjustment is necessary.
nelfinavir/dolutegravir
No dose adjustment is necessary.
sulfametoksazol:
No dose adjustment is necessary.
tipranavir+ritonavir/
No dose adjustment is needed (see section 5.2).
Odmerka ni treba prilagajati (glejte poglavje 5.2).
No dose adjustment is needed for elderly patients (see section 4.4).
Pri starostnikih ni potrebno prilagajati odmerkov (glejte poglavje 4.4).
No dose adjustment is needed for elderly patients.
Starejšim bolnikom odmerka ni treba prilagoditi.
No dose adjustment is needed for INTELENCE.
Prilagajanje odmerka zdravila INTELENCE ni potrebno.
No dose adjustment is needed for Kaletra.
glavnih značilnosti zdravila za
No dose adjustment is needed for lopinavir/ritonavir.
Zdravila za zdravljenje protina
No dose adjustment is needed for patients 65 years of age and older (see section 5.2).
Pri bolnikih, starih 65 let ali več, prilagajanje odmerka ni potrebno (glejte poglavje 5.2).
No dose adjustment is needed for patients with mild or moderate renal impairment.
Bolnikom z blago do zmerno okvaro ledvic odmerka ni treba prilagoditi.
No dose adjustment is needed for patients with mild to moderate hepatic impairment.
Pri bolnikih z blago do zmerno jetrno okvaro prilagoditev odmerka ni potrebna.
No dose adjustment is needed in elderly (≥75 years) patients.
Pri starejših bolnikih (≥ 75 let) odmerka ni treba prilagajati odmerka.
No dose adjustment is needed in elderly patients (see section 5.2).
Pri starejših bolnikih prilagoditev odmerka ni potrebna (glejte poglavje 5.2).
No dose adjustment is needed in elderly patients.
Pri starejših bolnikih odmerka ni treba prilagajati.
No dose adjustment is needed in patients based on weight.
Odmerka ni treba prilagoditi glede na bolnikovo telesno maso.
No dose adjustment is needed in patients with hepatic impairment (see section 5.2)
Bolnikom z okvaro jeter odmerka ni treba prilagoditi (glejte poglavje 5.2).
No dose adjustment is needed in patients with hepatic impairment (see section 5.2).
Bolnikom z okvaro jeter odmerka ni treba prilagoditi (glejte poglavje 5.2).
No dose adjustment is needed in patients with mild and moderate renal impairment.
Pri bolnikih z blago in zmerno okvaro ledvic ni potrebno prilagajanje odmerka.
No dose adjustment is needed in patients with mild or moderate hepatic impairment (Child-Pugh classes A and B).
Pri bolnikih z blago ali zmerno okvaro jeter odmerka ni treba prilagajati (razred A ali B po Child- Pughu).
No dose adjustment is needed in patients with mild to moderate hepatic impairment.
Na razpolago ni nobenih podatkov.
No dose adjustment is needed in patients with mild, moderate or severe renal insufficiency (see section 4.4 and section 5.2).
Pri bolnikih z blago, zmerno ali hudo ledvično insuficienco odmerka ni treba prilagajati (glejte poglavje 4.4 in poglavje 5.2).
No dose adjustment is needed in patients with renal insufficiency.
Pri bolnicah z ledvično insuficienco ni potrebno prilagajanje odmerka.
No dose adjustment is normally required for elderly patients.
Pri starejših bolnikih običajno ni potrebna nikakršna prilagoditev odmerka.
No dose adjustment is recommended (see section 4.2).
Odmerka ni potrebno prilagajati (glejte poglavje 4.2).
No dose adjustment is recommended based on age (see section 5.2).
Na podlagi starosti ne priporočajo nikakršnega prilagajanja odmerjanja (glejte poglavje 5.2).
No dose adjustment is recommended based on age alone.
Samo na podlagi starosti prilagajanje odmerka ni potrebno.
No dose adjustment is recommended based on age.
Prilagoditev odmerka na osnovi starosti ni potrebna.
No dose adjustment is recommended based solely on age (see also sections 5.1 and 5.2).
Odmerka ni treba prilagoditi samo zaradi starosti(glejte tudi poglavji 5.1 in 5.2).
No dose adjustment is recommended for individuals older than 65 years of age (see section 5.2).
Pri osebah, starejših od 65 let, odmerka ni treba prilagajati (glejte poglavje 5.2).
No dose adjustment is recommended for patients with mild hepatic impairment.
Pri bolnicah z blago jetrno okvaro prilagajanje odmerka ni priporočljivo.
No dose adjustment is recommended for patients with mild or moderate hepatic impairment (see sections 4.4 and 5.2).
Za bolnike z blago do zmerno okvaro jeter ni priporočenega prilagajanja odmerka (glejte poglavji 4.4 in 5.2).
No dose adjustment is recommended for patients with mild or moderate renal impairment (see sections 4.4 and 5.2).
Za bolnike z blago do zmerno okvaro delovanja ledvic ni priporočenega prilagajanja odmerka (glejte poglavji 4.4 in 5.2).
No dose adjustment is recommended for patients with mild renal impairment.
Pri bolnikih z blago okvaro ledvic ni priporočil za prilagoditev odmerka.
No dose adjustment is recommended for patients with renal impairment (see section 5.2).
Pri bolnikih z okvaro ledvic odmerka ni treba prilagajati (glejte poglavje 5.2).
No dose adjustment is recommended for this patient population (see sections 4.4 and 5.2).
Za to skupino bolnikov ni priporočenega prilaganja odmerka (glejte poglavji 4.4 in 5.2).
No dose adjustment is recommended for underweight or obese subjects.
Bolnikom s premajhno telesno maso in debelim bolnikom odmerka ni treba prilagoditi.
No dose adjustment is recommended in patients with mild and moderate renal impairment.
Bolnikom z blago ali zmerno okvaro ledvic odmerka ni treba prilagoditi.
No dose adjustment is recommended in patients with mild hepatic impairment (total bilirubin ≤upper limit of normal (ULN) and aspartate aminotransferase (AST) >ULN or total bilirubin >1.0 to 1.5x ULN and any AST) but caution should be used when administering TAGRISSO to these patients.
Bolnikom z blago okvaro jeter (celokupni bilirubin ≤ zgornja meja normalne vrednosti (ZMN) in aspartat aminotransferaza (AST) > ZMN ali celokupni bilirubin > od 1- do 1,5-kratne ZMN ne glede na AST) odmerka ni treba prilagoditi, vendar je treba zdravilo TAGRISSO pri teh bolnikih uporabljati previdno.
No dose adjustment is recommended in patients with mild to moderate renal impairment (see sections 4.4 and 5.2).
Pri bolnikih z blago do zmerno ledvično okvaro prilagoditev odmerka ni potrebna (glejte poglavji 4.4 in 5.2).
No dose adjustment is recommended when used with moderate or weak CYP3A inducers.
Pri uporabi z zmernimi ali šibkimi spodbujevalci CYP3A prilagajanja odmerka ne priporočajo.
No dose adjustment is recommended when used with moderate or weak CYP3A inhibitors.
Pri uporabi z zmernimi ali šibkimi zaviralci CYP3A prilagajanja odmerka ne priporočajo.
No dose adjustment is recommended.
Prilagajanje odmerkov ni potrebno.
No dose adjustment is recommended.
Prilagoditev odmerka ni
No dose adjustment is recommended.
priporočljiva.
No dose adjustment is recommended.
zmanjšanim odmerkom didanozina
No dose adjustment is required
Prilagoditev odmerka ni potrebna,
No dose adjustment is required (see section 5.1).
Prilagoditev odmerka ni potrebna (glejte poglavje 5.1).
No dose adjustment is required (see section 5.2 ).
Prilagajanje odmerkov ni potrebno (glejte poglavje 5.2).
No dose adjustment is required (see section 5.2).
Prilagajanje odmerkov ni potrebno (glejte poglavje 5.2). .
No dose adjustment is required (see sections 5.1 and 5.2).
Prilagajanje odmerka ni potrebno (glejte poglavji 5.1 in 5.2).
No dose adjustment is required based on age (see section 5.2).
Prilagoditev odmerka na osnovi starosti ni potrebna (glejte poglavje 5.2).
No dose adjustment is required based on age.
Odmerka ni treba prilagoditi glede na starost.
No dose adjustment is required following the switch from an efavirenz-containing regimen.
Po prehodu z režima, ki vsebuje efavirenz, odmerka ni treba prilagoditi.
No dose adjustment is required for elderly patients.
Pri starejših bolnikih odmerjanja ni treba prilagoditi.
No dose adjustment is required for elotuzumab in patients over 65 years of age (see section 5.2).
Pri bolnikih, starejših od 65 let, odmerka elotuzumaba ni treba prilagajati (glejte poglavje 5.2).
No dose adjustment is required for hepatically-impaired COPD patients.
Za bolnike s KOPB z okvarami jeter ni potrebno prilagajanje odmerka.
No dose adjustment is required for lopinavir/ritonavir during pregnancy and postpartum.
Med nosečnostjo in po porodu ni potrebna prilagoditev odmerka lopinavirja/ritonavirja.
No dose adjustment is required for lopinavir/ritonavir during pregnancy and postpartum.
Med nosečnostjo in po porodu prilagoditev odmerka lopinavirja/ritonavirja ni potrebna.
No dose adjustment is required for patients with cancer-related pain (see sections 4.3 and 4.4).
Bolnikom, ki imajo bolečine zaradi raka, odmerka ni potrebno prilagoditi (glejte poglavji 4.3 in 4.4).
No dose adjustment is required for patients with hepatic impairment (see section 5.2).
Pri bolnikih z okvaro jeter odmerka ni treba prilagajati (glejte poglavje 5.2).
No dose adjustment is required for patients with hepatic impairment.
Pri bolnikih z okvaro jeter ni treba prilagajati odmerka.
No dose adjustment is required for patients with mild hepatic impairment.
Pri bolnikih z blago okvaro jeter ni potrebna prilagoditev odmerka.
No dose adjustment is required for patients with mild renal impairment (CLCR ≥50 to ≤80 ml/min).
Pri bolnikih z blago okvaro delovanja ledvic (CLCR ≥50 do ≤80 ml/min) prilagoditev odmerka ni potrebna.
No dose adjustment is required for patients with renal impairment (see section 5.1).
Pri bolnikih z okvaro ledvic prilagajanje odmerka ni potrebno (glejte poglavje 5.1).
No dose adjustment is required for patients with renal impairment.
Pri bolnikih z ledvično okvaro običajno ni potrebna nikakršna prilagoditev odmerka.
No dose adjustment is required for patients with renal impairment.
Pri bolnikih z okvaro ledvic ni potrebna prilagoditev odmerka.
No dose adjustment is required for patients with renal impairment.
Pri bolnikih z okvaro ledvic prilagajanje odmerjanja ni potrebno.
No dose adjustment is required for pomalidomide.
Odmerka pomalidomida ni treba prilagajati.
No dose adjustment is required for this patient population (see sections 4.8 and 5.2).
Pri tej skupini bolnikov ni potrebno prilagajanje odmerka (glejte poglavji 4.8 in 5.2).
No dose adjustment is required for thrombocytopenic patients with chronic HCV and mild hepatic impairment (Child-Pugh score ≤ 6).
Pri trombocitopeničnih bolnikih s kroničnim HCV in blago okvaro jeter (ocena po Child-Pugh-u ≤ 6) prilagoditev odmerka ni potrebna.
No dose adjustment is required in elderly (see section 5.2).
Starejšim bolnikom odmerka ni treba prilagoditi (glejte poglavje 5.2).
No dose adjustment is required in elderly patients (see section 5.2).
Starejšim bolnikom odmerka ni treba prilagoditi (glejte poglavje 5.2).
No dose adjustment is required in hepatically impaired patients (see section 5.2).
Bolnikom z jetrno okvaro odmerka ni treba prilagajati (glejte poglavje 5.2).
No dose adjustment is required in older people ≥ 65 years of age.
V skupini starejših ljudi, starih ≥ 65 let, ni potrebno prilagajanje odmerka.
No dose adjustment is required in patients aged 65 years and older.
Bolnikom, starim 65 let ali več, odmerka ni treba prilagoditi.
No dose adjustment is required in patients with hepatic impairment (see section 5.2).
Bolnikom z jetrno okvaro odmerka ni treba prilagajati (glejte poglavje 5.2).
No dose adjustment is required in patients with hepatic impairment (see section 5.2).
Pri bolnikih z jetrno okvaro prilagajanje odmerka ni potrebno (glejte poglavje 5.2).
No dose adjustment is required in patients with hepatic impairment (see section 5.2).
Pri bolnikih z okvaro jeter odmerka ni treba prilagajati (glejte poglavje 5.2).
No dose adjustment is required in patients with hepatic impairment (see sections 4.4 and 5.2).
Pri bolnikih z jetrno okvaro ni potrebno prilagajanje odmerkov (glejte poglavji 4.4 in 5.2).
No dose adjustment is required in patients with hepatic impairment (see sections 4.4 and 5.2).
Prilagoditev odmerka ni potrebna pri bolnikih z jetrno okvaro (glejte poglavji 4.4 in 5.2).
No dose adjustment is required in patients with hepatic impairment(see section 5.2).
Bolnikom z jetrno okvaro odmerka ni treba prilagajati (glejte poglavje 5.2).
No dose adjustment is required in patients with impaired renal function (see section 5.2).
Pri bolnikih z okvarjenim delovanjem ledvic prilagajanje odmerkov ni potrebno (glejte poglavje 5.2).
No dose adjustment is required in patients with impaired renal function at creatinine clearance
Odmerka ni treba prilagoditi bolnikom z okvarjenim delovanjem ledvic, ki imajo očistek kreatinina
No dose adjustment is required in patients with mild (Estimated Glomerular Filtration Rate [eGFR] 60-90 ml/min/1.73 m2) renal impairment.
Pri bolnikih z blago okvaro ledvic (z ocenjeno hitrostjo glomerulne filtracije 60-90 ml/min/1,73 m2) prilagajanje odmerjanja ni potrebno.
No dose adjustment is required in patients with mild hepatic impairment.
Bolnikom z blago okvaro jeter odmerka ni treba prilagoditi.
No dose adjustment is required in patients with mild or moderate hepatic impairment (see section 5.2).
Bolnikom z blago ali zmerno okvaro jeter odmerka ni treba prilagoditi (glejte poglavje 5.2).
No dose adjustment is required in patients with mild or moderate renal impairment (see also section 5.2).
Pri bolnikih z blago ali zmerno okvaro ledvic odmerka ni treba prilagajati (glejte tudi poglavje 5.2).
No dose adjustment is required in patients with mild to moderate renal impairment (creatinine clearance [CrCl] 30-89 mL/min) (see section 5.2).
Bolnikom z blago do zmerno ledvično okvaro (očistek kreatinina 30–89 ml/min) odmerka ni treba prilagoditi (glejte poglavje 5.2).
No dose adjustment is required in patients with mild to moderate renal impairment who are receiving pirfenidone.
Pri bolnikih z blago do zmerno okvaro ledvic, ki prejemajo pirfenidon, odmerka ni treba prilagajati.
No dose adjustment is required in patients with mild, moderate or severe hepatic impairment defined based on National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG)- criteria for hepatic impairment: mild:total bilirubin (TB) ≤ upper limit of normal (ULN), aspartate aminotransferase (AST)>ULN or ULN<TB≤1.5xULN, AST any moderate: 1.5 x ULN < TB < 3 x ULN, AST any severe: 3 x ULN < TB < 10 x ULN, AST any (see section 5.2)
Odmerka ni treba prilagoditi bolnikom z blago, zmerno ali hudo jetrno okvaro glede na merila NCI- ODWG (National Cancer Institute Organ Dysfunction Working Group) za jetrno okvaro: blaga: celokupni bilirubin (CB) ≤ zgornja meja normale (ZMN), aspartat aminotransferaza (AST) > ZMN ali ZMN < CB ≤ 1,5 x ZMN, ne glede na AST, zmerna: 1,5 x ZMN < CB < 3 x ZMN, ne glede na AST, huda: 3 x ZMN < CB < 10 x ZMN, ne glede na AST (glejte poglavje 5.2).
No dose adjustment is required in patients with mild, moderate or severe renal impairment, or end stage renal disease.
Pri bolnikih z blago, zmerno ali težko ledvično okvaro ali končno ledvično odpovedjo ni potrebno prilagajanje odmerka.
No dose adjustment is required in patients with mild-to-moderate renal impairment (30-70 ml/min creatinine clearance) (see sections 4.4 and 5.2).
Za bolnike z blago do zmerno ledvično okvaro (očistek kreatinina 30 do 70 ml/min) odmerka ni treba prilagajati (glejte poglavji 4.4 in 5.2).
No dose adjustment is required in patients with renal impairment (see section 5.2).
Pri bolnikih z ledvično okvaro ni potrebna prilagoditev odmerka (glejte poglavje 5.2).
No dose adjustment is required in patients with renal impairment (see section 5.2).
Pri bolnikih z ledvično okvaro prilagajanje odmerka ni potrebno (glejte poglavje 5.2).
No dose adjustment is required in patients with renal impairment (see sections 4.4 and 5.2).
Pri bolnikih z okvaro ledvic prilagajanje odmerka ni potrebno (glejte poglavji 4.4 in 5.2).
No dose adjustment is required in patients with renal impairment (see sections 4.4 for recommendations relating to monitoring of calcium).
Bolnikom z okvaro ledvic odmerka ni treba prilagoditi (za priporočila o spremljanju kalcija glejte poglavje 4.4).
No dose adjustment is required in patients with renal impairment, including those patients with end-stage renal disease.
Pri bolnikih z okvaro ledvic ni potrebna prilagoditev odmerka; to vključuje bolnike s končno ledvično odpovedjo.
No dose adjustment is required in patients with renal impairment.
Pri bolnikih z ledvično okvaro ni potrebno prilagoditi odmerka.
No dose adjustment is required in RA patients.
Za bolnike z RA ni potrebna prilagoditev odmerka.
No dose adjustment is required in relation to age (see section 5.2)
Prilagoditev odmerka glede na starost ni potrebna (glejte poglavje 5.2).
No dose adjustment is required in the elderly (see section 5.2).
Pri starostnikih odmerka ni treba prilagajati (glejte poglavje 5.2).
No dose adjustment is required in the elderly population.
Prilagajanje odmerka za starejše bolnike ni potrebno.
No dose adjustment is required in this population (see section 5.2).
Pri bolnikih z okvaro ledvic odmerka ni treba prilagajati (glejte poglavje 5.2).
No dose adjustment is required in this population (see section 5.2).
Pri starejših bolnikih odmerka ni treba prilagajati (glejte poglavje 5.2).
No dose adjustment is required on the basis of patient age (see section 5.2).
Odmerka ni treba prilagoditi glede na starost (glejte poglavje 5.2).
No dose adjustment is required when NovoThirteen is used in paediatric patients and the dose of 35 IU/kg body weight should be used (see section 5.2 ‘Paediatric population’).
Pediatričnim bolnikom odmerka zdravila NovoThirteen ni treba prilagoditi, uporabiti pa je treba odmerek 35 i.e./kg telesne mase (glejte poglavje 5.2, "Pediatrična populacija").
No dose adjustment is required when Stribild is co-administered with telaprevir.
Prilagoditev odmerka ni potrebna, če se zdravilo Stribild uporablja sočasno z telaprevirjem.
No dose adjustment is required when Tybost is co-administered with telaprevir.
Prilagoditev odmerka ni potrebna, če se zdravilo Tybost uporablja sočasno z telaprevirjem.
No dose adjustment is required when used in combination with other DMARDs, corticosteroids, salicylates, nonsteroidal anti-inflammatory drugs (NSAIDs), or analgesics.
Pri uporabi skupaj z drugimi imunomodulirajočimi protirevmatičnimi zdravili (DMARDs-disease-modifying anti-rheumatic drugs), kortikosteroidi, salicilati, nesteroidnimi protivnetnimi zdravili (NSAIDs-nonsteroidal anti-inflammatory drugs) ali analgetiki odmerka ni treba prilagoditi.
No dose adjustment is required,
Prilagoditev odmerka ni potrebna.
No dose adjustment is required, however, BUCCOLAM should be used with caution in patients with chronic renal failure as elimination of midazolam may be delayed and the effects prolonged. (see section 4.4)
Prilagajanje odmerka ni potrebno, vendar pa je treba zdravilo BUCCOLAM uporabljati previdno pri bolnikih s kronično ledvično odpovedjo, ker se lahko izločanje midazolama zakasni, učinki pa podaljšajo (glejte poglavje 4.4).
No dose adjustment is required, unless there is evidence of moderate or severe renal impairment.
Prilagajanje odmerkov ni potrebno, razen če ima bolnik zmerno ali hudo ledvično okvaro.
No dose adjustment is required.
Prilagajanje odmerkov ni
No dose adjustment is required.
Prilagoditev odmerka
No dose adjustment is required.
Prilagoditev odmerka metadona ni potrebna.
No dose adjustment is required.
Prilagoditev odmerka ni
No dose adjustment is required.
Prilagoditev odmerka ni priporočljiva.
No dose adjustment is required.
Za bolnike z RA ni potrebna prilagoditev odmerka.
No dose adjustment is required. (see section 5.2).
Prilagajanje odmerkov ni potrebno (glejte poglavje 5.2).